Skip to main content
. Author manuscript; available in PMC: 2022 Jun 13.
Published in final edited form as: Neuropharmacology. 2020 Jan 7;167:107933. doi: 10.1016/j.neuropharm.2019.107933

Table 1.

Summary of the head twitch response (HTR) data from dose-response experiments.

Compound ANOVA Time (min) Dose (mg/kg) N HTR Counts (Mean ± SEM) ED50 mg/kg (95% CI) ED50 μmol/kg (95% CI)
DOMa F(5,23)=17.1, p<0.0001 30 0 5 4.6 ± 0.9 0.43 (0.30–0.62) 1.75 (1.22–2.52)
0.1 5 17.4 ± 1.7
0.3 5 52.6 ± 8.0
1 5 118.0 ± 14.5 **
3 5 126.8 ± 24.4 **
10 4 27.0 ± 8.6

DOETa F(4,22)=7.68, p=0.0005 30 0 6 7.5 ± 1.7 0.20 (0.11–0.36) 0.77 (0.43–1.37)
0.1 5 34.8 ± 8.7
0.3 5 86.2 ± 9.6 *
1 6 122.0 ± 29.3 **
3 5 71.0 ± 14.2 *

DOBUc F(4,26)=36.68, p<0.0001 30 0 7 6.6 ± 1.9 1.17 (0.99–1.38) 4.64 (3.92–5.50)
0.3 6 13.0 ± 2.5
1 6 46.3 ± 6.3 **
3 6 111.8 ± 12.4 **
10 6 25.5 ± 7.7

DOCa F(3,18)=23.92, p<0.0001 30 0 6 8.2 ± 1.4 0.32 (0.21–0.47) 1.19 (0.80–1.77)
0.3 5 64.0 ± 2.0 **
1 6 125.3 ± 13.5 **
3 5 89.8 ± 16.3 **

R-(-)-DOIa F(4,23)=25.14, p<0.0001 30 0 7 9.4 ± 1.7 0.24 (0.17–0.33) 0.66 (0.47–0.93)
0.1 5 27.2 ± 3.1
0.3 6 89.2 ± 12.0 **
1 5 132.0 ± 17.0 **
3 5 97.0 ± 12.8 **

DONa F(4,20)=7.65, p=0.0007 30 0 5 6.4 ± 2.3 1.31 (0.70–2.43) 4.72 (2.54–8.77)
0.3 5 17.4 ± 3.4
1 5 43.0 ± 1.2
3 5 102.8 ± 6.9 **
10 5 96.2 ± 34.9 **

MDAa F(4,22)=3.53, p=0.0227 30 0 6 6.2 ± 1.4 1.46 (0.72–2.98) 6.77 (3.33–13.8)
0.3 5 6.6 ± 1.2
1 5 9.6 ± 1.1
3 6 16.7 ± 2.4 *
10 5 15.0 ± 5.1

R-(-)-MDAa F(4,23)=8.11, P=0.0003 30 0 6 7.8 ± 1.4 1.45 (0.82–2.54) 6.71 (3.82–11.8)
0.3 5 8.6 ± 1.5
1 6 15.5 ± 3.2
3 6 30.0 ± 6.2 **
10 5 27.6 ± 2.8 **

α-Et-2C-Da F(4,23)=3.95, P=0.0139 30 0 5 9.4 ± 2.6 4.09 (2.70–6.22) 15.8 (10.4–23.9)
3 6 14.2 ± 4.1
6 5 25.4 ± 4.9 *
12 6 26.0 ± 2.2 *
24 6 14.5 ± 4.0

25D-NBOMea F(5,28)=10.57, P<0.0001 30 0 6 6.2 ± 0.8 0.23 (0.12–0.43) 0.64 (0.34–1.22)
0.03 5 12.2 ± 2.9
0.1 6 39.2 ± 7.5
0.3 6 45.0 ± 12.5
1 6 96.7 ± 17.2 **
3 5 85.6 ± 18.9 **

25I-NBOHa F(5,24)=8.90, P<0.0001 30 0 5 4.4 ± 1.4 0.085 (0.055–0.132) 0.19 (0.12–0.29)
0.03 5 22.8 ± 3.1
0.1 5 48.8 ± 4.7 *
0.3 5 95.6 ± 14.2 **
1 5 64.0 ± 12.6 **
3 5 44.4 ± 17.0

5-MeO-AMTa F(4,22)=10.65, p<0.0001 30 0 6 4.3 ± 0.8 0.53 (0.25–1.11) 2.21 (1.06–4.60)
0.1 5 9.4 ± 2.8
0.3 5 11.0 ± 3.0
1 6 45.0 ± 11.4 **
3 5 50.4 ± 7.4 **

DMTb F(4,21)=41.25, p<0.0001 30 0 6 6.5 ± 2.4 1.54 (1.08–2.19) 5.05 (3.55–7.19)
0.3 5 11.4 ± 1.8
1 5 25.2 ± 3.5 *
3 5 65.6 ± 8.6 **
10 5 76.4 ± 6.2 **

DETb F(5,25)=6.20, p=0.0007 20 0 6 3.5 ± 0.5 2.28 (1.57–3.30) 6.85 (4.72–9.93)
0.625 5 4.0 ± 1.5
1.25 5 4.6 ± 1.9
2.5 5 13.0 ± 3.6 *
5 5 18.8 ± 3.0 **
10 5 13.0 ± 3.7 *

DPTa F(4,20)=4.02, p=0.0150 20 0 5 4.4 ± 0.5 1.90 (1.14–3.19) 6.78 (4.04–11.4)
0.625 5 6.4 ± 1.5
1.25 5 7.8 ± 2.7
2.5 5 26.2 ± 7.1 *
5 5 24.8 ± 9.0 *

DIPTa F(4,22)=8.9, p=0.0002 30 0 6 6.0 ± 0.4 2.40 (1.67–3.44) 8.54 (5.96–12.2)
1.25 5 16.6 ± 4.3
2.5 5 27.6 ± 7.1
5 6 53.5 ± 5.3 **
10 5 40.8 ± 12.0 **
*

p < 0.05

**

p < 0.01, significant difference from the vehicle control group (Dunnett’s test).

a

Hydrochloride salt

b

fumarate salt

c

freebase.